Sarah Sungurlu

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/8d27d5c0-7e34-11ec-abab-b971dcc17ab8.jpg

First Name

Sarah

Last Name

Sungurlu

NPI

1174819478

Faculty ID

17214

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

165589

Visit Type ID

2542

Is Open Scheduling

On

Kate R. Steinberg

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/05b61a40-891d-11ec-a48a-e9e0c9e20faa.jpg

First Name

Kate

Last Name

Steinberg

NPI

1528488459

Faculty ID

16973

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

141643

Visit Type ID

2542

Is Open Scheduling

On

Michele St. Louis

https://assets.montefioreeinstein.org/profiles/images/physphoto/St_Louis_Michele_MD_420x504.jpg

First Name

Michele

Last Name

St. Louis

NPI

1265517395

Faculty ID

4894

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p><span style="font-family: 'Times New Roman'; font-size: medium;">Michele St Louis received her MD from New York University School Of Medicine and completed her internship and residency in Family Medicine at Montefiore Medical Center. She completed fellowships in Developmental Disabilities and Faculty Development in the Department of Family Medicine at Montefiore. She is director of the Montefiore School Health Program and sees patients at the school-based health center in Theodore Roosevelt High School. Her clinical and research interests include health promotion and reproductive health care, including access to and satisfaction with long-acting reversible contraception (LARC) in adolescents. She is a Clinical Assistant Professor in Family Medicine.</span></p>
<p><strong>Education</strong></p>
<p>Undergraduate: Sophie Davis School of Biomedical Education, City College of New York, Bachelor&rsquo;s Degree in Biomedical Science, Cum Laude<br />Medical School: New York University School of Medicine<br />Residency: Montefiore Medical Center (Family Medicine, Social Medicine)<br />Fellowships: Montefiore Medical Center (Developmental Disabilities Fellowship Program, Faculty Development Program)</p>
<p><strong>Professional Activity</strong></p>
<p>Dr. Michele St. Louis is Director of the Medical Division of the Montefiore School Health Program, and supervises residents and fellows in school-based health settings.</p>
<p>Her research focuses on teens' access to and acceptability of intrauterine devices in school-based health centers.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Selected Publications

<p>Patient Satisfaction with IUD Services in a School Based Health Center: A Pilot Study. Tara B Stein, MD, MPH, Aleza K Summit, MPH, Michele St Louis, MD, Marji Gold, MD Journal of Pediatric and Adolescent Gynecology, Vol 33, Issue 4, p 388-392 Jan 2020</p>

EMR ID

3707

Is Open Scheduling

Off

Simon D. Spivack

https://assets.montefioreeinstein.org/profiles/images/Spivack_Simon_MD_2x.jpg

First Name

Simon

Last Name

Spivack

NPI

1366438475

Faculty ID

11003

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>&nbsp;</p>
<p>Focusing diagnostics and therapeutics on those most likely to benefit is a key to successful intervention&nbsp;at both the public health and clinical levels. The translational goal of the Spivack laboratory is to identify individuals at particularly high risk for lung malignancy, and selected non-malignant lung diseases, upon whom to focus smoking/toxin exposure cessation (primary prevention), chemoprevention (secondary prevention), and early disease detection efforts (disease screening, tertiary prevention).</p>
<p>The laboratory is currently exploring individual Gene x Environment signatures as susceptibility markers by exploring quantitative gene (mRNA) expression phenotypes, and the DNA sequence, methylation, microRNA, and other epigenetic features potentially underlying these expression phenotypes, <em>in vitro</em> and in human populations. This is performed in the setting of defined tobacco, diet, and other exposures. There are both mechanistic and translational components to the studies.&nbsp;</p>
<p><br /><strong>Mechanistically</strong>, the role of epigenetic variation in promoter regions in the 5' and 3' regulatory regions of carcinogenesis and oxidant pathway genes is being explored <em>in vitro</em>, using human genomic DNA reporter constructs, and native gene regulation models. High resolution technologies include the realtime quantitation of native mRNA and microRNA by the laboratory's RNA-specific strategy (<em>patented</em>); the&nbsp;tagged-bisulfite genomic sequencing strategy to determine single base resolution CpG methylation status (tBGS, <em>patented</em>);&nbsp;&nbsp;an experimental strategy for assaying microRNA binding to mRNA, for determining the role of miRNA in candidate gene regulation&nbsp;(<em>patented</em>); and evaluation of functional consequences of DNA&nbsp;methylation detail, using a novel patch reporter construct (<em>patented</em>).&nbsp; A new method to engineer methyl-cytosines into the epigenome has recently been developed.</p>
<p>Whole (epi)genome approaches to identify molecular events unique to lung cancer&nbsp;are being completed, which will represent one of the initial cross-platform 'omics level discovery examinations of&nbsp;lung&nbsp;tissues.&nbsp; The execution of each individual discovery platform involves&nbsp;expert local collaborators and cores&nbsp;in (epi)genetics and genomics, and the "integromics" is critically reliant on Einstein strengths in informatics and biostatistical analyses.</p>
<p>&nbsp;</p>
<p><strong>Translationally</strong>, human lung carcinogenesis biomarkers are being established by pairing laser capture microdissected lung with several unique, non-invasively collected surrogate specimens developed in the laboratory. These include mRNA expression signatures from brush-exfoliated buccal mucosa cells, microRNAs detected in exhaled breath condensate representing first reports for a new exhaled airway biomarker class, and exhaled metabolomic signatures. These airway-derived specimens continue to accrue from a sampling (currently n&gt;1000) of a population assembled in a lung cancer case-control context.&nbsp; The specimens are being studied with a view toward developing non-invasive assays in populations.</p>
<p>&nbsp;</p>
<p>The overall aim is to develop informative non-invasive risk profiling, preventive, and early disease detection strategies for the lung in human populations.</p>
<p>&nbsp;</p>
<p>&nbsp;<em>Work is funded by ongoing NIH,</em><em> DoD,&nbsp;and&nbsp;Foundation support.</em></p>
<p>&nbsp;</p>
<p><strong>Clinical Specialties</strong></p>
<ul style="font-size: 1em; color: #333333; padding: 0px; margin: 20px 0px 25px 38px;">
<li style="padding: 0px; margin: 12px 0px 5px 0px;">lung nodule evaluation</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">lung cancer diagnostics and screening</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">interstitial lung disease</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">environmental lung disease</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">refractory asthma</li>
<li style="padding: 0px; margin: 12px 0px 5px 0px;">general pulmonary medicine</li>
</ul>

Research Areas

Expert Tags

Areas of Expertise

Expert Summary

<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">A researcher and clinician, Dr. Spivack is developing tests for detecting lung cancer at the earliest possible stage&mdash;before it becomes fatal by spreading to other parts of the body. In one of several NIH-funded studies, his laboratory is working on a noninvasive, early-diagnosis test for lung cancer that detects particular genetic elements and chemicals in exhaled breath.</span></p>
<p class="MsoNormal" style="line-height: 15.6pt;"><span style="font-size: 9.0pt;">In addition to general pulmonary medicine, Dr. Spivack&rsquo;s clinical practice focuses on lung nodule and lung cancer diagnosis, diffuse interstitial lung diseases, and environmental lung diseases.</span></p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Spivack specializes in consultative pulmonary medicine, with an emphasis on the evaluation of lung nodules, lung cancer screening, asthma, and environmental and interstitial lung disease.<span style="color:#4d4d4d;font-family:Arial, Helvetica, source-code-pro, Menlo, Monaco, Consolas, 'Courier New', monospace;font-size:16px;background-color:#ffffff;"><strong></strong></span>

Research Focus

Dr. Spivack&rsquo;s research focuses on the development of non-invasive early detection airway biomarkers of lung cancer risk, as well as epigenetics, gene regulation, gene-environment interaction and non-invasive measurement of deep lung phenomena in humans.

Elsevier Profile

Selected Publications

<p>&nbsp;</p>
<p><strong><span style="text-decoration: underline;">Selected Publications, as of April, 2023</span>:</strong></p>
<p class="MsoNormal"><span style="text-indent: -0.25in;">Shi M, Han W, Loudig O, Shah C, Dobkin J, Keller S, Sadoughi A, Patel D, Desai A, Gombar S, Suh Y, Fernandez MK, DeLaRosa L, Wang T, Hosgood D, Pradhan K, Ye K, </span><strong style="text-indent: -0.25in;">Spivack SD.</strong><span style="text-indent: -0.25in;">&nbsp; </span><span style="text-indent: -0.25in;">(2023) Initial development and testing of an exhaled microRNA detection strategy for lung cancer case-control discrimination</span><em style="text-indent: -0.25in;">. [accepted, Scientific Reports, NPG]</em></p>
<p class="MsoNormal" style="margin-bottom: 1.7pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
<p class="MsoNormal" style="margin-bottom: 1.7pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;"><span style="color: #212121; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">Huang Z, Sun S, Lee M, Maslov AY, Shi M, Waldman S, Marsh A, Siddiqui T, Dong X, Peter Y, Sadoughi A, Shah C, Ye K, *<strong>Spivack SD</strong>, *Vijg J. Single-cell analysis of somatic mutations in human bronchial epithelial cells in relation to aging and smoking. Nat Genet. 2022 Apr;54(4):492-498. doi: 10.1038/s41588-022-01035-w. Epub 2022 Apr 11. PMID: 35410377. (*co-senior authors).</span></p>
<p class="MsoNormal" style="margin-bottom: 1.7pt; background-image: initial; background-position: initial; background-size: initial; background-repeat: initial; background-attachment: initial; background-origin: initial; background-clip: initial;">&nbsp;</p>
<p class="MsoNormal"><span style="font-variant-numeric: normal; font-variant-east-asian: normal; font-stretch: normal; font-size: 7pt; line-height: normal; font-family: 'Times New Roman';">&nbsp;</span><!--[endif]--><span lang="EN">Cleven KL, Ye K, Zeig-Owens R, Hena KM, Montagna C, Shan J, Hosgood HD 3rd, Jaber N, Weiden MD, Colbeth HL, Goldfarb DG, <strong>Spivack SD</strong>++, Prezant DJ++ (++co-senior authors). </span><a href="https://www.ncbi.nlm.nih.gov/pubmed/31126090"><span lang="EN" style="color: windowtext; text-decoration-line: none;">Genetic Variants Associated with FDNY WTC-Related Sarcoidosis.</span></a><span lang="EN"> Int J Environ Res Public Health. 2019 May 23;16(10). pii: E1830. doi: 10.3390/ijerph16101830. PMID:31126090</span>.</p>
<p>Dong X, ShiN, LeeM, ToroR, Gravina S, Han W, Yasuda S, Wang T, Zhang Z, Vijg J, Suh Y, <strong>Spivack SD.</strong> (2018) Global, integrated analysis of methylomes and transcriptomes from laser capture microdissected bronchial and alveolar cells in human lung. <em>Epigenetics </em>10.1080/15592294.2018.1441650, 2018.</p>
<p>Mullapudi N, Ye B, Suzuki M, Wang T, Fazarri M,&nbsp;Han W, Shi M, Marquardt G, Lin J, Wang T,&nbsp;Keller S, Zhu C, Locker&nbsp;J, &nbsp;<strong>Spivack SD.</strong> Genome-wide methylome alterations in lung cancer&nbsp;<em> PLoS ONE, </em>Dec. 2015.</p>
<p>Lin J, Marquardt G, Mullapudi N,&nbsp;Wang, T,&nbsp;Han W, Shi W, Zhu C, Keller S,&nbsp;Zhu C,&nbsp;Locker J, <strong>Spivack SD. </strong>Lung cancer transcriptomes refined with laser capture microdissection.<em>&nbsp;Am J Pathology </em>06.028.&nbsp;2014 .</p>
<p>Han W, Shi M, <strong>Spivack SD</strong>. Site-specific methylated reporter constructs for functional analysis of DNA methylation.<em> Epigenetics </em>4; 8(11), 2013.</p>
<p>Shi M, Han W, <strong>Spivack SD</strong>. A quantitative method to identify miRNAs targeting an mRNA using a 3'UTR RNA affinity technique.<em> Analytic Biochem</em>&nbsp;1;443(1):1-12, 2013<em>.</em></p>
<p>Alberg AJ, Brock MV, Ford JG, Samet JM, <strong>Spivack, SD.</strong>&nbsp;&nbsp;Epidemiology of lung cancer.&nbsp; In Evidence-based Practice Guidelines. Diagnosis and Management of Lung Cancer (ACCP position statement). <em>CHEST</em>.&nbsp;&nbsp;May 2013;143(5 Suppl):e1S-e29S. doi: 10.1378/chest.12-2345. PMID: 23649439.</p>
<p>Tan XT, Marquardt G, Shi M, Han W, <strong>Spivack SD.</strong> High throughput library screening identifies phytochemical inducers of phase II mutagen/oxidant metabolism enzymes GSTP1 and NQO1 in human lung cells.<em> Am J Resp Cell Molec Biol, </em>46(3): 365-71, 2012.</p>
<p>Brock GJ,&nbsp;Moschos S, <strong>Sp</strong><strong>ivack SD,</strong> Hurteau GJ.&nbsp;The 3' prime paradigm of the miR-200 family and other microRNAs. <em>Epigenetics</em> (6:3, 1-5), 2011.</p>
<p>Tan XT, &nbsp;Shi M, &nbsp;Minna JD,&nbsp; Han W,&nbsp; <strong>Spivack SD.</strong> Candidate phytopreventive agent modulation of phase II metabolism enzymes <em>GSTP1</em> and <em>NQO1</em> in human bronchial cells<em>. J Nutrition,&nbsp;</em>140(8): 1404-10, 2010<em>.</em></p>
<p>Tan, XT, &nbsp;&nbsp;Wang T,&nbsp; Xiong S,&nbsp; Kumar SV,<strong>&nbsp;</strong> Han W, &nbsp;<strong>Spivack SD.</strong> &nbsp;Smoking-related gene expression in laser capture microdissected human lung. <em>Clin Cancer Res,</em> 15(24): 7562-70, 2009.</p>
<p>Han W, Tang T, Reilly AA, Keller S, <strong>Spivack SD</strong>. Gene promoter methylation analyses from exhaled breath, with differences in smokers and lung cancer cases.&nbsp; <em>Resp Res,</em> 10:86 epubl, 2009.</p>
<p>Tan X-L,&nbsp; Moslehi R, Han W, <strong>Spivack SD</strong>. Haplotype tagging single nucleotide polymorphisms in the glutathione S-transferase P1 gene promoter and susceptibility to lung cancer. <em>Cancer Detection Prev,</em>32:403-415, 2009<em>.</em></p>
<p>Tan X-L,&nbsp;&nbsp;<strong>Spivack SD</strong>. Dietary chemoprevention strategies for&nbsp;induction of phase II metabolism: a review. <em>Lung Cancer,</em>65(2):129-37, 2009.</p>
<p>Hurteau GJ, Carlson AJ, <strong>Spivack, SD,</strong> Brock GJ. Restoration of E-Cadherin expression by over-expression of the microRNA <em>hsa-miR-200c</em> via reduced expression of the transcription factor TCF8. <em>Cancer Res.</em> 67:7972-76, 2007.</p>
<p>Hurteau, GJ, <strong>Spivack</strong> <strong>SD</strong>, Brock G.&nbsp; Parallel identification of miRNA and target mRNA by combined informatics and qRT-PCR approaches: application to <em>has-miR-200c.</em>&nbsp; <em>Cell Cycle</em> 5(17):1951-56, 2006.</p>
<p>Han W, Cauchi S, Herman JG, <strong>Spivack SD</strong>.&nbsp; Methylation mapping of DNA by tag-modified bisulfite genomic DNA sequencing. <em>Analytic Biochem. 355: 50-61,</em> 2006.</p>
<p>Cauchi S, Han W, Kumar SV, <strong>Spivack SD</strong>. Haplotype-environment interactions regulating the human <em>GSTP1</em> promoter <em>Cancer Res</em>. 66(12): 6439-6448, 2006.</p>
<p>Kumar SV, Hurteau GJ, <strong>Spivack SD.</strong> Validity of mRNA expression analyses of human saliva. <em>Clin. Cancer Res.</em> 12: 5033-39, 2006.</p>
<p><strong>Spivack SD</strong>, Hurteau GJ, Jain R, Kumar SV, Aldous KM, Gierthy JF, Kaminsky LS.&nbsp; Gene-environment interaction signatures by quantitative mRNA profiling in exfoliated buccal mucosal cells. <em>Cancer Res,</em> 64:6805-6813, 2004.</p>
<p><strong>Spivack SD</strong>, Hurteau GJ, Fasco MJ, Kaminsky LS.&nbsp; Phase I and II carcinogen metabolism gene expression in human lung tissue and tumors.&nbsp; <em>Clinical Cancer Research</em>, 9:6002-6011, 2003.</p>
<p>&nbsp;</p>

EMR ID

4969

Biography

<p>Simon D. Spivack, MD, MPH, is Professor, Medicine, Epidemiology and Genetics at Montefiore Einstein. He is also former Emeritus Chief, Pulmonary Medicine. Clinically, Dr. Spivack specializes in consultative pulmonary medicine, with an emphasis on the evaluation of lung nodules, lung cancer screening, asthma, and environmental and interstitial lung disease. </p><p>After obtaining his Bachelor of Science in Psychobiology from McGill University in Montreal, Canada in 1980, Dr. Spivack earned his Doctor of Medicine from the State University of New York Upstate Medical University in 1985. He then completed an internship and residency in internal medicine at the University of Massachusetts Medical Center in 1988. Dr. Spivack then earned his Master of Public Health at Harvard University, School of Public Health in 1989. He completed a clinical pulmonary and critical care medicine and lung research fellowship at the University of Vermont in 1992. </p><p>Dr. Spivack&rsquo;s research focuses on the development of non-invasive early detection airway biomarkers of lung cancer risk, as well as epigenetics, gene regulation, gene-environment interaction and non-invasive measurement of deep lung phenomena in humans. His work has been published in numerous peer-reviewed journals, articles, chapters and books, and he has given many national/international presentations, organized symposia and visiting professorships. Dr. Spivack is on the Editorial Board for Scientific Reports and is a reviewer for journals such as <em>PLoS Genetics</em>, <em>Genetics in Medicine</em>, <em>Nature Protocols</em>, <em>American Journal of Respiratory &amp; Critical Care Medicine</em>, <em>Carcinogenesis</em>, <em>Cancer Research</em> and others. He holds multiple United States patents. He has been continually funded by the National Institutes of Health (NIH) for research for over 25 years.
</p><p>Dr. Spivack is board certified in internal medicine, pulmonary medicine and critical care medicine. He is a member of the American Thoracic Society (ATS), the American Association for Cancer Research (AACR) and the American Lung Association (ALA). He is a frequent peer-reviewer on various NIH study sections. In the past, Dr. Spivack won the Excellence in Research Award from ALA and the NIH/National Institute of Environmental Health Sciences (NIEHS) Clinical Scientist Development Award.

</p>

Visit Type ID

2542

Is Open Scheduling

On

Zocdoc Link

Jenny Shliozberg

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/b4de2cd0-35dc-11ed-82c6-41b469a7b495.jpg

First Name

Jenny

Last Name

Shliozberg

NPI

1174603971

Faculty ID

1191

CMO Specialties

Clinical Terms

Employment Status

part-time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

EMR ID

3597

Biography

<p>Jenny Shliozberg, MD, is an attending physician at the Children&rsquo;s Hospital at Montefiore Einstein and Associate Professor, Pediatrics at our Albert Einstein College of Medicine. Her clinical focus is in food allergy, hereditary angioedema (HAE), asthma, rhinitis, oral allergy syndrome and chronic urticaria. She frequently conducts food and drug challenges and has cared for HIV-positive and immunodeficient patients for the last 35 years.
</p><p>After earning her Doctor of Medicine at First Pavlov Medical University in St. Petersburg, Russia, Dr. Shliozberg continued with her postgraduate training at the same institution, completing her internship in obstetrics and gynecology followed by an ambulatory obstetrics and gynecology clinic. She later came to the United States, continuing her postgraduate training in 1984, completing a pediatric residency at Beth Israel Medical Center in 1987 and an allergy and immunology fellowship at Montefiore and Einstein in 1989.
</p><p>Dr. Shliozberg&rsquo;s research focus includes food allergy, HAE, chronic sporadic urticaria, study in pediatric asthma, HIV and severe combined immunodeficiency and eosinophilic esophagitis. She is principal investigator on the use of Dupixent for pediatric patients, and has a study on AIR Supra use in children. Dr. Shilozberg has shared her work through peer-reviewed journals, book chapters, abstracts, posters and case reports and she has presented internationally and nationally. She has trained more than 70 fellows, many residents and medical students throughout her career.
</p><p>Dr. Shliozberg is board certified by the American Board of Allergy and Immunology. She is a Fellow of the American Academy of Allergy, Asthma and Immunology and the American College of Allergy, Asthma and Immunology. Dr. Shliozberg is a member of the American Association of Certified Allergists, the New York Allergy Society, and the Clinical Immunology Society.

</p>

Is Open Scheduling

On

Zocdoc Link

Alan J. Shapiro

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Alan

Last Name

Shapiro

NPI

1750467601

Faculty ID

3487

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Male

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

3661

Is Open Scheduling

Off

Chirag D. Shah

https://assets.montefioreeinstein.org/profiles/images/physphoto/Shah_Chirag_MD_420x504.jpg

First Name

Chirag

Last Name

Shah

NPI

1164629770

Faculty ID

15234

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5732

Visit Type ID

2542

Is Open Scheduling

On

Theresa M. Serra

https://assets.montefioreeinstein.org/profiles/images/Serra_Theresa_MD_2x.jpg

First Name

Theresa

Last Name

Serra

NPI

1609164078

Faculty ID

14280

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Clinical Focus

Pediatric Medicine

Elsevier Profile

EMR ID

55674

Biography

<p class="MsoNormal">Theresa Serra, MD, joined the CHAM hospitalist division in 2014 after working as a pediatric hospitalist at New York Presbyterian/Lower Manhattan Hospital. Her interests include clinical research and medical education. She has conducted an IRB approved retrospective chart review examining readmission rates in pediatric patients diagnosed with osteomyelitis. Dr. Serra is currently developing a medical Spanish curriculum for faculty members in order to improve communication between patients, families and providers. Along with Courtney McNamara, MD, Dr. Serra is a co-leader of a multidisciplinary committee dedicated to standardizing and improving quality of care for patients hospitalized with the diagnosis of failure to thrive. Dr. Serra is also working on an initiative to identify vaccine delinquency in the inpatient setting through the use of SMART reports.</p> <p class="MsoNormal">Dr. Serra is also collaborating with Lindsey Douglas, MD, MSCR, in an IRB approved quality improvement (QI) project to improve transition-of-care communication between hospitalists and primary care providers and to facilitate the establishment of medical homes. Dr. Serra is also a member of a subcommittee that leads monthly journal clubs/case conferences for pediatric hospitalists.</p>

Is Open Scheduling

Off

Amrita K. Seehra

https://assets.montefioreeinstein.org/profiles/images/default-profile-blue.svg

First Name

Amrita

Last Name

Seehra

NPI

1538548060

Faculty ID

17827

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

29409

Is Open Scheduling

Off

Robin L. Scott

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/4e97a850-c3de-11eb-9ea2-7374238588d1.jpg

First Name

Robin

Last Name

Scott

NPI

1841376795

Faculty ID

5376

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Pediatric

Department

Gender

Female

Provider Type

Primary Care

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

On

Professional Title

Elsevier Profile

EMR ID

4128

Is Open Scheduling

Off